{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(4)"],"submitter":["Zhao Y"],"funding":["Sunshine Guojian Pharmaceutical (Shanghai) Co.,Ltd"],"pubmed_abstract":["<h4>Introduction</h4>Atopic dermatitis (AD) is a chronic inflammatory skin disease. 611, a humanized monoclonal antibody, selectively targets the interleukin (IL)-4 receptor alpha, thereby inhibiting the signaling of both interleukin (IL)-4 and IL-13. This phase 2 study aimed to evaluate the efficacy and safety of 611 in Chinese adults with moderate-to-severe AD.<h4>Methods</h4>This randomized, double-blind, placebo-controlled phase 2 study was conducted between October 2022 and September 2023. Eligible patients with moderate-to-severe AD were randomly assigned in a 1:1:1 ratio to receive 611 at a dose of either 300 mg (loading dose of 600 mg) every 2 weeks (Group A) or 300 mg (loading dose of 600 mg) every 4 weeks (Group B), or placebo every 2 weeks for 16 weeks, followed by an 8-week fol"],"journal":["Dermatology and therapy"],"pagination":["857-867"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11971068"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial."],"pmcid":["PMC11971068"],"pubmed_authors":["Ji C","Wu L","Li J","Liu L","Zhou Q","Zhang J","Feng Y","Huang H","Yang B","Zhang L","Zhao Y","Xiao R","Ji M","Ding Y","Zhu J","Hu G","Duan X","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial.","description":"<h4>Introduction</h4>Atopic dermatitis (AD) is a chronic inflammatory skin disease. 611, a humanized monoclonal antibody, selectively targets the interleukin (IL)-4 receptor alpha, thereby inhibiting the signaling of both interleukin (IL)-4 and IL-13. This phase 2 study aimed to evaluate the efficacy and safety of 611 in Chinese adults with moderate-to-severe AD.<h4>Methods</h4>This randomized, double-blind, placebo-controlled phase 2 study was conducted between October 2022 and September 2023. Eligible patients with moderate-to-severe AD were randomly assigned in a 1:1:1 ratio to receive 611 at a dose of either 300 mg (loading dose of 600 mg) every 2 weeks (Group A) or 300 mg (loading dose of 600 mg) every 4 weeks (Group B), or placebo every 2 weeks for 16 weeks, followed by an 8-week fol","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-02T06:36:21.724Z","creation":"2025-07-08T03:13:50.639Z"},"accession":"S-EPMC11971068","cross_references":{"pubmed":["40057938"],"doi":["10.1007/s13555-025-01368-4"]}}